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Background: Genes that regulate stem cell function are suspected to exert adverse effects on prognosis in malignancy.
However, diverse cancer stem cell signatures are difficult for physicians to interpret and apply clinically. To connect
the transcriptome and stem cell biology, with potential clinical applications, we propose a novel computational
“gene-to-function, snapshot-to-dynamics, and biology-to-clinic” framework to uncover core functional gene-sets
signatures. This framework incorporates three function-centric gene-set analysis strategies: a meta-analysis of both
microarray and RNA-seq data, novel dynamic network mechanism (DNM) identification, and a personalized prognostic
indicator analysis. This work uses complex disease acute myeloid leukemia (AML) as a research platform.
Results: We introduced an adjustable “soft threshold” to a functional gene-set algorithm and found that two different
analysis methods identified distinct gene-set signatures from the same samples. We identified a 30-gene cluster that
characterizes leukemic stem cell (LSC)-depleted cells and a 25-gene cluster that characterizes LSC-enriched cells in
parallel; both mark favorable-prognosis in AML. Genes within each signature significantly share common biological
processes and/or molecular functions (empirical p = 6e-5 and 0.03 respectively). The 25-gene signature reflects the
abnormal development of stem cells in AML, such as AURKA over-expression. We subsequently determined that
the clinical relevance of both signatures is independent of known clinical risk classifications in 214 patients with
cytogenetically normal AML. We successfully validated the prognosis of both signatures in two independent cohorts
of 91 and 242 patients respectively (log-rank p < 0.0015 and 0.05; empirical p < 0.015 and 0.08).
Conclusion: The proposed algorithms and computational framework will harness systems biology research because
they efficiently translate gene-sets (rather than single genes) into biological discoveries about AML and other
complex diseases.
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Acute myeloid leukemia (AML) has a high mortality
rate. Leukemic stem cells (LSC) represent a rare self-
renewing cellular subpopulation in each AML. Their
chemo-resistant properties are associated with adverse
outcomes [1,2]. However, the key events that confer* Correspondence: xyang2@uchicago.edu
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Still, gene expression markers for LSC among studies
lack reproducibility, although the characterization of
these genes is likely to reveal novel and tractable targets
to improve treatment outcomes [3-5].
We hypothesize that one main limitation is that there
is no definitive method to isolate LSC from bulk cell
samples, and therefore, methods attempting to identify
LSC signature are limited by cell heterogeneity. To
overcome this problem, we have developed a novelhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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framework has a four-fold advantage: i) It enables multi-
resource data integration and biologically functional
interpretation by working on the scale of functional
gene-sets; ii) It defines a cluster of functionally interpret-
able gene-sets shared among LSC populations generated
by different labs; iii) It identifies mutual functional rela-
tionships from a network of spatiotemporally (disease
developmentally) dynamic expression; iv) It provides a
personalized leukemic prognostic indicator derived from
the identified gene-set clusters. Here, we present the
method and demonstrate its application to identify a
common LSC signature. The identified LSC-associated
biomarkers have a direct link to biological interpretation
and clinical application.
First, to facilitate multi-resource data integration and
biologically functional interpretation, knowledge-centric
analysis (or the analysis of gene-sets) was developed
by us and others, e.g., GSEA (Gene Set Enrichment
Analysis) [6-8]. The analysis of gene-sets is superior to
single-gene analysis in regard to noise and dimension re-
duction, as well as its desired biological interpretability
[9]. However, most gene-set analysis methods impose
inherent limits on low cross-dataset comparison or
reproducibility from gene-by-sample measurements,
as only the genes measured by all collected platforms
can be interrogated together. Improved gene-set analyses
condense transcriptomic data from gene-by-sample
measurements (gene profiles) to gene-set-by-sample
measurements (gene-set profiles), which are gene-
coverage-difference tolerable and a breakthrough in
genome analytics coordinates. Such gene-set-by-sample
analyses facilitate the integration and analysis of multiple
datasets, platforms, or layers of omics-data, by assigning
them into a uniform gene-set scale [10-13]. Some
transcription-focused methods, such as GSVA (Gene Set
Variation Analysis), condense gene expression values into
gene-set scores by evaluating sample-wise enrichments.
Yet an open question is the sample-wised statistics before
calculating gene-set scores, which limits a mechanistic
representation of individual samples. To overcome these
deficiencies, we have developed a gene-set-by-sample
algorithm, FAIME (Functional Analysis of Individual
Microarray (or RNA-seq) Expression) [7,8]. Note that
for each sample, FAIME compares the cumulative effects
of genes inside a gene-set with the effects of those out-
side. Additionally, FAIME employs an expression-based
weight to rectify biases introduced by low-valued genes
[14], and thus quantifies gene-sets primarily according to
its highly expressed gene members. However, sensitivity
remains a challenge as, at a significance level of false dis-
covery rate (FDR) of 0.05, FAIME could identify hun-
dreds of gene-sets, an impractical number for wet-lab
validation. Therefore, we introduce in this study a newweighting parameter into the FAIME algorithm to
better control the type-I error, especially for small
gene-sets. Additionally, the integration of microarray
and RNA-seq data is a new task that we have per-
formed in this study, given the increase in their pub-
lication and availability.
Second, dynamic network biomarker (DNB) analysis
has been developed on the gene level to address the
challenge of temporal and spatial gene expression profil-
ing. It identifies the disease biomarkers leading the
whole system from the normal state to a disease state
[15,16]. Here, we demonstrate the first dynamic network
biomarker analysis on the gene-set level (termed dy-
namic network mechanism – DNM analysis). These
gene-set-based network-relationship dynamics (rather
than the static featured single gene-set up- or down-
regulations) translate seemingly uninterpretable genomic
data into distinct clinical prognoses. In particular, the
identified gene-sets define a new biomarker for the char-
acterized stem cell sub-population.
Finally, the goal of cancer treatment is to improve
outcomes by earlier diagnosis and targeted therapy for
each patient. We have developed the relative expres-
sion concept to build a personalized prognostic indi-
cator on the gene level [17,18]. In this study, we
expand the concept of relative expression to gene-set
clusters and identify a prognostic indicator evaluated
by three large cohorts. Meta-analysis is a powerful so-
lution in identifying common LSC signatures shared
among different LSC subpopulations with the chal-
lenge of small sample size and high cell heterogeneity.
In this study, we pool sorted samples from eight labs,
including microarray and RNA-seq data, into three
groups: HSC+ (verified hematopoietic stem cells enriched,
n = 23), LSC+ (LSC enriched, n = 77), and LSC- (LSC de-
pleted, n = 59) cells. Enlarged sample size ensures reliable
detection.
Molecular Signature Database (MSigDB) [19] is the
most popular gene-set database that defines groups of
genes associated with a common function, pathway or
other characteristics using biological evidence. Built on
MSigDB-defined gene-sets and the above four strategies
(Figure 1), we generated gene-set profiles using FAIME
(with a weighting parameter) and identified a cluster of
three gene-sets with 30 genes representative for LSC-.
We also generated gene-set profiles using the GSVA
method and identified another cluster of three functional
gene-sets with 25 genes in LSC+. The genes within each
cluster of gene-sets display simultaneous co-variation
with high mutual correlation exclusively within the cor-
responding cell subpopulations. Using available samples
of primary AML patients, we further assessed the clin-
ical relevance by prognosis and the biological relevance
by ontology for both gene sets.
Figure 1 Flowchart of normalization and analysis of pooled molecular function profiles. Panel A) Collection of gene expression profiles.
Datasets (D) of Acute Myeloid Leukemia (AML) positive or negative (1 and 2 respectively) for Leukemia Stem Cell (LSC), and of normal Hematopoietic
Stem Cells (HSC) (3). Panel B) Calculation of gene-set profiles. Panel C) Identification of functional gene-sets associated with LSCs using the dynamic
network mechanism analysis. A cartoon shows that different features characterize the dramatic systems stage changes in different ways. Panel D)
Evaluation of clinical relevance in primary AML samples. Panel E) Evaluation of biological relevance using independent data resources.
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Improved functional gene set profiles and the inter-dataset
normalization allow cross-dataset comparisons
Some GSEA algorithms (e.g., the Bioconductor package
PGSEA) suggest an applicable gene-set (GS) size ranging
from 25 to 500 genes. However, half of the canonical
pathways have only 10–30 gene members (MSigDB). Tocontrol the type-I error when testing on small GSs ef-
fectively, we improved the FAIME algorithm with a new
adjusted parameter α (hereafter termed as FAIME.5
when α = 5). The larger α is, the higher the weight for
the genes at the extreme top of expression ranks is, ex-
ponentially (Figure 2B). The parameter α thus acts as a
“soft threshold” [20]. Previous studies have shown that
Figure 2 (See legend on next page.)
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Figure 2 FAIME algorithm with a new parameter α outline. Panel A) The input for the FAIME algorithm is either a gene expression matrix in
the form of log2 microarray expression values or RNA-seq counts, and a database of gene-sets. Panel B) Mechanism (or gene-set) score is defined
as the difference between the scored expression of genes inside and outside a previously defined gene-set. B-1) Applying an increasingly
larger α to the FAIME method. The weight (y-axis) is an exponential function of gene expression ranks (x-axis) adjusted by the parameter α. B-2)
Weight-dependent qualitative scores sharply increase with gene rank. The score (y-axis) is the product of gene expression ranks (x-axis) and the
rank’s weight adjusted by the parameter α. In each panel, the more highly expressed genes are ranked higher on the x-axis. The dashed line
represents the score obtained with no weighting (i.e., ranking only). Panel C) Output of the algorithm as a matrix containing mechanism scores
for each gene-set and sample.
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statistical power to that of the GSEA algorithm [7,21].
We compared FAIME.α with GSEA and GSVA in a
simulation study. By empirically testing three integers
(1,5, and 10) as candidate α values, we chose α = 5.
FAIME.5 provided a better control of type-I errors than
FAIME.1 but a higher accuracy than FAIME.10 for small
GSs with less than 30 genes (Additional file 1: Figure S1,
Additional file 2: Text S1: S Results 1.1). Even GSEA,
FAIME and GSVA identified distinct GSs in an initial
two-group comparison test, FAIME.1 and FAIME.5
shared over half of their identified GSs, and the FAIME
shared more identified GSs with GSEA than GSVA (data
not shown). Given that FAIME and GSVA have exhib-
ited better or comparable statistical power to that of the
GSEA algorithm in certain conditions of previous
studies [7,21], we used FAIME.5 and GSVA in the subse-
quent LSC study. A vignette file with R source codes
(Additional file 3: Text S2) shows how to run FAIME.α
on a Bioconductor available gene expression dataset,
using the MSigDB defined gene-sets of CGP (chemical
and genetic perturbations) as a demo.
The required sample size for functional gene set ana-
lysis was also discussed in the simulation study. With at
least 20 samples per group, the three methods (FAIME,
GSEA, and GSVA) could identify repeatable signatures
in the scenarios in which half or more of genes in a GS
exhibit strong signal-to-noise ratio (Additional file 1:
Figure S1- C,D, dashed lines). Therefore, to ensure stat-
istical power, we collected more than 20 samples per
group (of microarray or RNA-seq data (Table 1 and
Additional file 4: Table S1) - and performed meta-
analysis on the GS level. Meta-analysis is one solution
for the limited number of LSC+ sub-populations and
their heterogeneity across studies. This study further
meets an outstanding need to characterize LSC be-
cause, on average, only 16% (2%-28%, Additional file 1:
Figure S2A) of reported LSC+ gene signatures were re-
peatable across five previous studies that attempted to
distinguish malignant LSC in AML [1,22-24].
To make the samples per group from disparate resources
comparable, we applied a straightforward inter-dataset
normalization (z-transfer) on mechanism profiles that var-
ied across observed datasets (Additional file 1: Figure S3).For both FAIME and GSVA methods, this inter-dataset
normalization reduces the cross-sample variance re-
gardless of gene-set sizes and re-scales gene-set scores
to be symmetric and zero-centered (Additional file 1:
Figure S3B). Subsequently, the majority of such normal-
ized gene-set scores met the null hypothesis of conven-
tional statistical models designed for gene expression,
which is that few genes differ between phenotypes.
Therefore, we can employ statistical models designed
for gene expression profiles on these gene-set profiles,
ensuring direct evaluation of gene-set significance with
phenotypes. However, using the conventional hypergeo-
metric test on 1320 canonical pathways each with five
or more genes from the MSigDB (v4.0), we observed a
large number exhibiting significant scores between two
sub-populations (e.g., 210 FAIME-derived pathways
meet the criteria of FDR < 0.05 and FC > 2, Bioconduc-
tor Limma package), suggesting the need for a proper
model to concentrate on core pathways.
Dynamic network mechanism (DNM) analysis defines new
LSC-representative signatures
To explore critical disease developmental signatures
using the gene-set profiles, we developed a dynamic
network mechanism (DNM) analysis. The hypothesis
is that the deteriorations of patient’s condition in
complex diseases such as AML are abrupt during the
progression of disease and may be caused by a critical
transition at a tipping point [15]. DNM is built on a
method, called dynamical network biomarker (DNB),
previously designed to capture early-warning signals
before a critical transition from normal state to dis-
ease state [15,16]. The DNM analysis identified gene-
sets are hereafter referred to as DNM gene-sets.
Given gene-set profiles of populations with different
disease states, the DNM analysis searches for the crit-
ical sub-network that exhibits a low variability and
high dependence intra-population, but high variability
and low dependence inter-population. Specifically, we
evaluated the network nodes (the gene-sets) by the
standard deviations for variability and pairwise Pearson
correlation coefficients for dependence among three differ-
ent cell sub-populations: HSC+, LSC+, and LSC- cells. We
thereafter identified the critical transitional sub-population
Table 1 Summary of collected transcriptional and clinical data for AML LSC+, AML LSC-, and normal HSC+ samples
GAL CBX21 GSE24006 GSE30377 GSE17054 ETABM978 GSM651554 Group
1st author Gal Ishikawa F Gentles AJ Eppert K Majeti R Goardon N Hu
Journal Leukemia JAMA JAMA leukemia Nature Med PNAS Cancer Cell Genome Res
Year 2006 2010 2011 2011 2009 2011 2011
PMID 17039238 17952057 21177505 21873988 19218430 21251617 21795385




N/A NOD/SCID or NSG N/A
AML LCS+ (CD34 + CD38- 8 13 LSC+ (n = 77)
AML LCS+ (CD34-CD38-) 3
AML LCS+ (CD34-CD38+) 1
AML LCS+ (CD34 + CD38+) 8
AML LCS+ (Lin-CD34 + CD38-CD90-)
AML LCS+ (Lin-CD34 + CD38-CD90-CD45RA+) 22
GMP-like AML LSC+ (Lin-CD34 + CD38 +
CD123+/loCD110-CD45RA + CD45RA+)
22
AML leukemia progenitor cell + (LPC+)
(hCD34 + hCD38+)
5 8 5 LSC- (n = 59)
AML CMP+ (Lin-CD34 + CD38+) 7 1 1
AML MPP+ (Lin-CD34 + CD38-CD90-CD45RA-) 2
AML Blasts (Lin-CD34-) 7 23
normal HSC+ (CD34 + CD133+) 1 normal HSC+ (n = 23)
normal HSC+ (Lin-CD34 + CD38-)
normal HSC+ (Lin-CD34 + CD38-)
normal HSC+ (Lin-CD34 + CD38loCD36-)
normal HSC+ (Lin-CD34 + CD38-CD90+) 4
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tinguish this sub-population from the other two using
a combined score of the variability and dependence of
gene-sets. As a result, a new 30-gene signature best
distinguishes the AML LSC- sub-population based on
FAIME.5 profiles, and a new 25-gene signature best
distinguishes the AML LSC+ population based on
GSVA profiles (Table 2). Note that the DNM identified
critical transitional sub-population from FAIME gene-
set profiles or GSVA gene-set profiles is different, sug-
gesting cell diversity. The number of involved genes
from identified gene-sets is a practical number for
wet-lab validation. Each signature is a cluster of 3 or 4
gene-sets showing simultaneous co-variation with mu-
tual correlation exclusively within the corresponding
cell subpopulations.
LSC- 30-gene signature
Based on the FAIME.5 profiles, DNM identified 3 out of
3403 gene-sets representing expression signatures of
chemical and genetic perturbations (CGPs) that distin-
guish LSC- cells from the other two cell subpopulations.
In the LSC- population, genes in those three gene-sets
exhibited different mutual correlations but lost many of
their original correlated partners from the normal HSC+
population (Figure 3A), defining a new 30 member
gene-set to represent LSC- exclusively.
Six (DLGAP5, RNASE2, CSTA, CPA3, CLC, MS4A3)
out of the 30 genes shared significant overlap across
the three gene-sets (p = 3.6e-15, Equation 7), indicat-
ing a functional cross-talk among the pre-defined
gene-sets. Subsequent Ingenuity® connection analysis
suggested that CDK1 and AURKA play the role of
‘hub’ in this 30-genes network. For example, the 30
genes included six candidate substrate proteins (MBD3,
CDC25B, LATS2, DLGAP5, AURKA, CENPA) of AURKA
[25] (Figure 3A, node f ). AURKA is a mitotic kinase
over-expressed in AML CD34 (+) /CD38 (−) cells
relative to their CD34 (+)/CD38 (+) counterparts or
CD34 (+) normal HSCs [26]. Given the clinical im-
pact of AURKA [26,27], the 30-gene signature reveals
promising molecular targets to eliminate chemotherapy-
resistance in LSC.
Also identified were two known gene-sets derived
from previous studies about LSC stemness (Additional
file 4: Table S2). One gene-set represents 11 genes
(SPC25, CPA3, NDC80, HGF, CSTA, CDK1, MS4A3,
MPO, RNASE2, CLC, TOP2A) down-regulated in the
quiescent CD34+ cells when compared to dividing CD34
+ cells isolated from the peripheral blood of myeloid
leukemia patients [28]. The other gene-set contains 19
LSC down-regulated genes (e.g., CD38, ZWINT, CCNA1)
when compared to leukemia progenitor cells from AML
tumor samples [22].LSC+ 25-gene signature
The GSVA profiles identified four correlated gene-sets,
consisting of 30 unique genes, that exclusively represent
LSC+ cells (Figure 3B, Additional file 4: Table S3).
One DNM gene-set, stem cell proliferation-2 (Scp2)
[29], included six genes (DYNLL2, GGNBP2, KIF1C,
MPO, PSMB6, and LOC728392) that were physically
mapped to the HSC proliferation quantitative trait locus
(QTL) on chromosome 11 in mouse models (Figure 3B,
node d). Scp2 is known to modulate the percentage of
cells in S phase, and deletions of its corresponding re-
gion in human (maps to 5q31.1) have been associated
with myelodysplastic syndrome and AML [29-31]. This
gene-set is negatively correlated with the other three
DNM gene-sets to represent LSC+ exclusively.
Another identified DNM gene-set contains five cancer
genes (CCND2, ERC1, KRAS, ZNF384, ETV6) in the
12p13-p11.1 region with co-localized fragile sites
(Figure 3B, node a). These amplified genes represent
attractive targets for therapy, diagnostics, and prog-
nostics [32]. This fact and the observation that 11 of
these 25 genes are also significantly involved in cell death
(ATXN3, CCND2, ERC1, ETV6, KIF1B, KIF1C, KRAS,
MAF, MPO, PIAS1, STK38, p = 0.0068, Ingenuity pathway
analysis - IPA, Ingenuity® Systems, www.ingenuity.com) in-
dicate a clinical impact for prognosis.
Note that the DNM analysis on the gene-set level is
designed to identify groups of genes with related func-
tions and correlated expressions, rather than clustering
samples on the gene-level. The expression changes of an
identified gene might be subtle in one dataset or uncov-
ered by its array. In fact, the joint gene-level expression
pattern of the DNM identified gene-sets exhibits a cor-
relation to data resources stronger than to cell types
(Additional file 1: Figure S4, Additional file 5: Text S3).
Regardless, the two identified gene clusters roughly
clustered samples into two groups: LSC- samples or
LSC+ samples. HSC+ samples are grouped together
in each dataset. These results support the feasibility
of using DNM analysis of an individual’s transcriptomic
changes on a gene-set level to reveal functional biomarkers
and biological underpinnings.
Clinical relevance - prognosis of DNM gene-sets in
patients with primary AML
To test the clinical relevance of the dynamic network
mechanism analysis identified LSC representative gene-
sets, we first investigated the gene-set profiles derived
from patients with all types of AML in three independ-
ent cohorts (GSE14468, n = 518 [33]; TCGA, n = 197
[34]; GSE12417, n = 242 [35]). Across the three cohorts,
increased scores of the identified gene-sets are associ-
ated with favorable overall survival, as log-regression
coefficients of both clusters of DNM gene-sets are
Table 2 Identified 30-gene and 25-gene signatures
Symbol Entrez gene name Type(s)^ Biomarker#^ Symbol Entrez gene name Type(s)^ Biomarker#^
LSC- 30 genes LSC+ 25 genes
ANLN anillin, actin binding protein other APPBP2 amyloid beta precursor protein
(cytoplasmic tail) binding protein 2
other
AURKA aurora kinase A kinase E ATXN3 ataxin 3 peptidase
CCNA1 cyclin A1 other CCND2 cyclin D2 other D, E
CCL5 chemokine (C-C motif) ligand 5 cytokine D, E, U DYNLL2 dynein, light chain, LC8-type 2 other
CD38 CD38 molecule enzyme E, P, U ERC1 ELKS/RAB6-interacting/CAST family
member 1
other
CDC25B cell division cycle 25B phosphatase ETV6 ets variant 6 transcription regulator
CDK1 cyclin-dependent kinase 1 kinase GGNBP2 gametogenetin binding protein 2 other
CENPA centromere protein A other GIMAP6 GTPase, IMAP family member 6 other
CLC Charcot-Leyden crystal galectin enzyme KIF1B kinesin family member 1B transporter
CPA3 carboxypeptidase A3 (mast cell) peptidase KIF1C kinesin family member 1C other
CSTA cystatin A (stefin A) other KRAS Kirsten rat sarcoma viral oncogene homolog enzyme D, E, P, R, U
DDX53 DEAD (Asp-Glu-Ala-Asp) box polypeptide 53 other LOC728392 uncharacterized LOC728392 other
DLGAP5 discs, large (Drosophila) homologassociated
protein 5
phosphatase MAF v-maf avian musculoaponeurotic
fibrosarcoma oncogene homolog
transcription regulator
HGF hepatocyte growth factor (hepapoietin A;
scatter factor)
growth factor D, DP, E, P, U MPO myeloperoxidase enzyme D, E, U
IL36B interleukin 36, beta cytokine MTERFD2 MTERF domain containing 2 other
KIAA0101 KIAA0101 other NAV1 neuron navigator 1 enzyme
LATS2 large tumor suppressor kinase 2 kinase PIAS1 protein inhibitor of activated STAT, 1 transcription regulator U
MBD3 methyl-CpG binding domain protein 3 other PSMB6 proteasome (prosome, macropain) subunit,
beta type, 6
peptidase
MND1 meiotic nuclear divisions 1 homolog
(S. cerevisiae)
other SESN1 sestrin 1 other
MPO myeloperoxidase enzyme D, E, U SLC30A7 solute carrier family 30 (zinc transporter),
member 7
transporter
MS4A3 membrane-spanning 4-domains, subfamily A,
member 3 (hematopoietic cell-specific)
other STK38 serine/threonine kinase 38 kinase
NDC80 NDC80 kinetochore complex component other TMIE transmembrane inner ear other
OLFM4 olfactomedin 4 other YARS2 tyrosyl-tRNA synthetase 2, mitochondrial enzyme
RNASE2 ribonuclease, RNase A family, 2
(liver, eosinophil-derived neurotoxin)
enzyme D ZBTB10 zinc finger and BTB domain containing 10 other












Table 2 Identified 30-gene and 25-gene signatures (Continued)
SKA3 spindle and kinetochore associated complex subunit 3 other
SPC25 SPC25, NDC80 kinetochore complex component other
STAR steroidogenic acute regulatory protein transporter
TOP2A topoisomerase (DNA) II alpha 170 kDa enzyme D, E, P, RT
ZWINT ZW10 interacting kinetochore protein other
#: D = diagnosis; DP = disease progression; P = prognosis; E = efficacy; RT = response to therapy; U = unspecified application.












Figure 3 (See legend on next page.)
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Figure 3 Dynamic Network Mechanism (DNM) analysis on functional gene-sets (gene-sets). Panel A) Network resulting from FAIME.5
profiles; Panel B) Network resulting from GSVA profiles. Each panel visually illustrates dynamics of the identified DNM gene-sets in each of the
three sorted cell groups (1: AML LSC +, 2: AML LSC-, and 3: normal HSC+). Node color codes the standard deviation of a gene-set in the
corresponding sample group, while line color codes the Pearson’s correlation coefficients between any two gene-sets. DNM gene-sets are
represented as labeled squares and control gene-sets are represented as circles. The identified critical sample group for each analytical
method is boxed in red (A1, B2). Line weight increases with correlation (>0.5 in Panel A and >0.4 in Panel B). Panel C) The colored groups of
gene-members (a, b, c, d) or (e, f, g) corresponding to the above red-boxed DNM gene-sets respectively. The grey lines represent their pair-wise
associations according to the Ingenuity knowledge database. Additional genes (black) that interacted with two or more identified genes in the
Ingenuity database are also displayed.
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therefore hypothesized that the patients’ survival can be
stratified by the identified DNM gene-sets and their se-
lected control gene-sets that stand for tumor suppressor
effects and tumorigenesis effects respectively. The con-
trols are gene-sets that are significantly correlated with
DNM gene-sets in normal HSC+ but not in LSCs cells,
the circled nodes in Figure 3A-B.
To validate that hypothesis, we designed a novel Relative
Effect Analysis with Gene-set Pairs (RXA-GSP) model,
built from a parameter-free model that we have designed
for personalized prognosis [17]. RXA-GSP calculates a
prognostic indicator comparing scores of the identified
gene-sets with scores of selected control gene-sets
(Equation 8). For each identified gene-set-cluster and
using the training cohort (GSE14468 [33]), we se-
lected from all the control gene-sets a prognostic
subset (p < 0.01, cox-regression coefficient > 0, Additional
file 4: Tables S2, and S3). We then validated the indicator
in two independent validation cohorts (TCGA [34];
GSE12417 [35]). Interestingly, a negative indicator sig-
nificantly predicted a shorter survival in both training
and the two validation cohorts. Additional file 1: Figure
S5A shows the Kaplan-Meier plots of the indicator built
from the gene-sets derived from FAIME.5 profiles (log-
rank p = 0.00043, 4.7e-6, and 0.00032 respectively; empir-
ical p = 0.007, 0.0045, and 0.007 by permuting random
gene-sets with the same number of genes respectively).
Note that the empirical p-value is more severe than the
log-rank tested p-value, as random signatures might also
predict cancer outcome [36]. This LSC-representative in-
dicator remained independent of all known prognostic
indicators including cytogenetic risk groups or European
LeukemiaNet (ELN) risk groups, using multivariate ana-
lyses on overall survival of primary AML patients in all
three cohorts (Table 3).
Next, we investigated the clinical relevance in pa-
tients with cytogenetically normal AML. A subclass of
intermediate-risk AML, cytogenetically normal AML has
a variety of outcomes: some affected individuals respond
well to standard treatment while others may require
more intensive therapy. We set the largest cytogenetically
normal AML cohort for training (GSE12417, n = 242cytogenetically normal AML [35]), and the other two
datasets as validation (GSE14468, n = 214 cytogenetically
normal AML [33]; TCGA, n = 91 cytogenetically normal
AML [34]). For the LSC- gene-sets, significance of three
out of four of the control gene-sets was repeatable, based
on the FAIME.5 profiles (Additional file 4: Table S2). The
observed prognosis (log-rank p = 0.0014, 0.0012, and
0.00082 respectively; empirical p = 0.014, 0.0045, and
0.013, respectively, Figure 4) remains significant in multi-
variate analysis, independent of age, KRAS mutation, and
ELN risk classification (Table 4).
Finally, we tested the relative effect analysis with
gene-set pairs on the four gene-sets that were derived
from the GSVA profiles to represent LSC+ cells. We
identified a significant prognostic indicator by train-
ing the control gene-sets using all AML patients
(Additional file 1: Figure S5B, log-rank p = 5.4e-5,
2.5e-5, and 0.05 respectively; empirical p = 0.002, 0.0005,
and 0.15 respectively). The indicator is independent of all
known clinic risk groups with an exception that it is
dependent on patient ages bipartitely at 60 years old
in the TCGA cohort (Additional file 4: Table S5).
Strikingly, this cytogenetically normal AML indicator
showed significance in two larger-sized validation data-
sets (Additional file 1: Figure S5C, log-rank p = 1.3e-10,
p = 0.0002, and 0.05 respectively; empirical p < 0.001,
0.001, and 0.08 respectively).
Additionally, as a side-by-side comparison with gene-
level signature, we tested the prognostic power of the
“LSC signature”, the weighted sum of 31 genes defined
by Gentles et al. [22]. In patients from GSE14468 and
GSE12417, high LSC scores were associated with worse
overall and event-free survival among patients with
either normal karyotypes or chromosomal abnormal-
ities (log-rank p < 0.002, Additional file 1: Figure S6
A1-A2, B), which is in agreement with previous pub-
lications. However, the patients in the TCGA cohort
exhibit an exception. Their survival could not be pre-
dicted using the LSC score (Additional file 1: Figure S6
A3, C). One possible explanation would be, at least
partly, the over-representation of mutations in the
TCGA cohort (99% compared to the expected 75%
in AML patients [37]). In contrast, our geneset-level
Table 3 Univariate and multivariate analyses of overall survival in patients with all types of AML, for the LSC- DNM
gene-sets
Dataset Variate model Variates HR 95% CI p-value
GSE14468 (n = 518) Univariate model 3 DNM fGSs vs 4 control fGSs 0.7 0.55-0.84 0.00043***
ELN_RiskFavorable vs. Adverse 0.3 0.20-0.40 2.15E-13***
complex vs. others 2.2 1.50-3.16 0.000024***
7q vs. others 2.1 1.45-2.97 0.000051***
ELN_RiskIntermediate-II vs. Adverse 0.5 0.36-0.70 0.000053***
Age group, years (≥60 vs. <60) 1.7 1.29-2.28 0.00016***
3q vs. others 2.1 1.32-3.42 0.0015**
ELN_RiskIntermediate-I vs. Adverse 0.6 0.46-0.86 0.0035**
inv16 vs. others 0.5 0.32-0.83 0.0057**
cebpa mutation vs. others 0.6 0.67-0.95 0.028*
Multivariate model 3 DNM fGSs vs 4 control fGSs 0.7 0.60-0.91 0.0050**
Age group, years (≥60 vs. <60) 1.7 1.26-2.29 0.00046***
ELN_RiskFavorable vs. Adverse 0.4 0.26-0.76 0.0034**
complex vs. others 1.6 0.96-2.58 0.07.
ELN_RiskIntermediate-II vs. Adverse 0.7 0.43-1.23 0.23
7q vs. others 1.3 0.82-2.09 0.26
3q vs. others 1.3 0.71-2.27 0.42
inv16 vs. others 0.8 0.47-1.39 0.44
cebpa mutation vs. others 0.9 0.53-1.45 0.61
ELN_RiskIntermediate-I vs. Adver 0.9 0.53-1.48 0.65
TCGA (n = 197) Univariate model 3 DNM fGSs vs 4 control fGSs 0.46 0.32-0.64 4.66E-06***
Age group, years (≥60 vs. <60) 3.02 2.16-4.21 9.94E-12***
gender 0.88 0.64-1.22 0.44
normal_karyotype vs. others 1.12 0.81-1.55 0.50
BM Blast(>50 vs. <=50) 0.88 0.60-1.30 0.53
Multivariate mode 3 DNM fGSs vs 4 control fGSs 0.60 0.42-0.86 0.0058**
Age group, years (≥60 vs. <60) 2.59 1.83-3.67 8.8E-08***
GSE12417 (n = 242) Univariate model 3 DNM fGSs vs 4 control fGSs 0.60 0.43-0.83 0.0021**
Age group, years (≥60 vs. <60) 1.63 1.18-2.26 0.0029**
Multivariate model 3 DNM fGSs vs 4 control fGSs 0.60 0.43-0.83 0.0021**
Age group, years (≥60 vs. <60) 1.49 1.07-2.07 0.018*
Significance code: ‘.’:p < .1; ‘*’: p < .05; ‘**’p < .01; ‘***’p < .001.
Significant univariate tested factors (p < .05) are used for multivariate test. Boldface highlights the results of DMN fGSs.
Yang et al. BMC Bioinformatics  (2015) 16:97 Page 12 of 21indicators showed unified prognoses in all three tested
cohorts.
Biological relevance – Gene Ontology similarity, AML
association, and correlation to RAS molecular activity
Gene Ontology (GO) provides curator-reviewed, stan-
dardized annotations for protein functions with a struc-
tured vocabulary. To evaluate co-functions of genes in
the identified gene-set cluster, we employed semantic
similarity of GO, a reliable computational method to ex-
ploit and classify coding gene functions (Additional file 2:Text S1: S Methods 2.4). For each DNM gene-set, two-
thirds of the identified genes share molecular functional
similarity or biological process similarity (semantic
similarity score = 1, Figure 5A), explicating their shared
dynamic phenotype in sorted cell populations and their
consistent prognosis in primary AML samples. The 30
LSC- representative genes are intensively connected by
75 paired molecular functional similarity (empirical
p = 6e-5, Figure 5A1), and the 25 LSC+ representative
genes are intensively connected by 17 paired biological
process similarity (empirical p = 0.03, Figure 5A2).
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Figure 4 Prognostic analysis of patients with cytogenetically normal AML, based on DNM identified gene-set pairs. Kaplan–Meier plots
of survival analysis on stratified samples with better outcome (green) or worse outcome (red). The Relative Effect Analysis with Gene-Set-Group
Pairs (RXA-GSP) calculated a prognostic indicator by comparing three LSC- representative gene-sets (30 genes) with three normal control gene-sets
(166 genes, Additional file 4: Table S2). The normalized FAIME.5 profiles are used. In each sub-panel, top bars mark the simulated p-values from which
we estimated the empirical p-value for the actually observed log-rank p-value, the vertical line marked with an arrow. A RXA-GSP indicator I of less than
1 significantly indicates worse prognosis in the training cohort (GSE12417, Panel A) of cytogenetically normal AML patients and in two validation
cohorts (GSE14468 and TCGA, Panels B and C) of cytogenetically normal AML patients.
Table 4 Univariate and multivariate analyses of overall survival in patients with cytogenetically normal AML, for the
LSC- DNM gene-sets
Dataset Variate model Variates HR 95% CI p-value
GSE12417 (n = 242) Univariate model 3 DNM fGSs vs. 4 control fGSs 0.53 0.35-0.79 0.0014**
Age group, years (≥60 vs. <60) 1.63 1.18-2.26 0.0029**
Multivariate model 3 DNM fGSs vs. 4 control fGSs 0.6 0.37-0.83 0.0038**
Age group, years (≥60 vs. <60) 1.6 1.12-2.15 0.0083**
GSE14468 (n = 214) Univariate model 3 DNM fGSs v.s 4 control fGSs 0.5 0.33-0.77 0.0012**
KRAS mutaion vs. others 70.2 7.30-674.5 8.60E-13***
ELN_risk (IntermediateI vs. Favorable) 1.8 1.27-2.62 0.00095***
Age group, years (≥60 vs. <60) 1.4 0.89-2.18 0.15
NPM1 mutation vs. others 0.8 0.57-1.12 0.19
CEBPA mutation vs. others 0.7 0.42-1.22 0.22
Gender 0.9 0.62-1.21 0.39
BM Blast (>50 vs. <=50) 1.1 0.76-1.53 0.68
NRAS mutation vs. others 1.0 0.60-1.81 0.90
Multivariate model 3 DNM fGSs v.s 4 control fGSs 0.5 0.35-0.83 0.0047**
KRAS mutaion vs. others 90.7 9.27-888.79 0.00011***
ELN_risk (IntermediateI vs. Favorable) 1.7 1.19-2.48 0.0039**
TCGA (n = 91) Univariate model 3 DNM fGSs vs. 4 control fGSs 0.4 0.19-0.67 8.23E-04***
Age group, years (≥60 vs. <60) 2.5 1.58-4.09 6.53E-05***
BM Blast (>50 vs. <=50) 0.6 0.33-1.09 0.09.
Gender 0.7 0.46-1.16 0.18
Multivariate model 3 DNM fGSs vs. 4 control fGSs 0.4 0.23-0.84 0.012*
Age group, years (≥60 vs. <60) 2.1 1.32-3.47 0.0022**
Significance code: ‘.’:p < .1; ‘*’: p < .05; ‘**’p < .01; ‘***’p < .001.
Significant univariate tested factors (p < .05) are used for multivariate test. Boldface highlights the results of DMN fGSs.
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Figure 5 The computationally evaluated biological relevance of genes in the identified gene-sets. Panel A) Genes in the identified cluster
of gene-sets share common functions. Sub-panel 1 represents the 30 LSC- representative genes and sub-panel 2 represents 25 LSC+ representative
genes. Gene Ontology semantic similarity analysis reveals that 2/3 of the genes share the same function (the Lin distance =1). Line color codes the
molecular function and biological process respectively. Panel B) Volcano plot (subpanel 1) of pairwise correlation tests between any two
LSC+ 25-gene members (TCAG data). There are 31 significant co-expressions across 10 AML patients who show positive RAS activity (dark
red). This co-expression disappears among the other 187 patients (grey), the 7 patients who carry somatic mutations of KRAS genes (blue),
and the 16 patients carrying positive RAS activity or somatic RAS mutation (orange). Subpanel 2 illustrates the RAS activity-dependent
co-expressed gene-pairs in a network. Comparing patients showing active molecular activity of RAS with patients showing normal RAS status,
31 pairs of genes gain significant co-expression, including 20 out of the 25 LSC+ representative genes (solid lines), whereas 1 gene-pair loses
its co-expression in normal RAS status (the dashed line). Red lines represent positive correlations and blue lines represent negative correlations.
Line widths correspond to Spearman correlation coefficients.
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vance of these gene-sets, we performed the Ingenuity
pathway analysis (IPA) on the 30- and 25-gene sets
respectively. Known cancer-related genes are over-
represented in both: the LSC- 30-gene signaturecontains 22 cancer-associated genes (p = 0.0056), in-
cluding three AML-associated genes (AURKA, MPO,
TOP2A, p = 0.0048); the LSC+ 25-gene signature con-
tains 10 cancer-associated genes, including another three
AML-associated genes (ETV6, KRAS, MPO, p = 0.002).
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we re-ran IPA on the remaining LSC- representative
(27-gene) subset and the remaining LSC+ representative
(22-gene) subset excluding known AML genes. Interest-
ingly, hematologic cancer genes (CCL5, CD38, CDK1,
HGF, IL36B, NDC80, p = 0.0032) and genes linked with cell
death of cancer cells (CD38, CDC25B, CDK1, p = 0.012)
were overrepresented in the LSC- representative subset.
Also, cancer cell transformation genes (CCND2, MAF,
ZNF384, p = 0.018) and interphase of tumor cell lines
(CCND2, PIAS1, STK38, ZBTB10, p = 0.000604) were
enriched in the LSC+ representative subset. This result
suggests a novel mechanism for AML tumorigenesis repre-
sented by these 30-gene and 25-gene signatures.
Finally, using available AML samples of the TCGA
cohort [34], we investigated the relationship between
the LSC+ 25-gene expression and the abnormal pro-
tein activity status of one gene member, RAS. The 25
genes gained co-expression (absolute Spearman coef-
ficient >0.6 and p < 0.05) significantly among patients
showing active RAS molecular activity (n = 10, empir-
ical p = 0.048) but not among those carrying KRAS
somatic mutation (n = 7, Additional file 4: Table S6)
nor among those with normal RAS activity status (n = 187,
Figure 5B).
We conclude that the LSC- signature of 30-gene or
the LSC+ signature of 25-gene significantly share bio-
logical processes and molecular functions. Although
mutations of RAS genes usually cause an intrinsic acti-
vation of RAS pathway in AML, it was RAS molecular
activity, not genetic mutation, that perturbed the LSC+
signature of 25-gene from that of the control. The litera-
ture suggests in parallel that it was RAS molecular activ-




Diverse signatures derived from the analysis of LSC
gene expression profiles at the gene level confirm the
heterogeneity of AML [5]. However, analyzing func-
tional gene-sets can reveal common networks that are
important for regulating LSC functions [39]. By meta-
analysis and inter-dataset normalization, we have im-
proved the reproducibility of characterizing clinically
relevant LSC-signatures on the gene-set level. The
other advantage of gene-set based algorithms is their
ability to build functional profiles, facilitating compu-
tational identification and subsequent biological inter-
pretation [7,21]. Building on gene-set-by-sample profiles,
we successfully integrated microarray and RNA-seq
data and performed two novel gene-set-analysis methods
to reveal critical gene-sets for disease diagnosis and
prognosis.A precise gene-set-by-sample profile is a necessary
prerequisite for functional class scoring approaches
(reviewed by Khatri et al. [40]). It is the pan-genome
weighting approach that more heavily weights highly-
expressed genes and thus distinguishes FAIME.α from
other gene-set analysis methods. Specifically, it biases of
not only extremely high-valued genes by ranking but
also the noise of low-valued genes by weighting, per
sample. GSVA, on the other hand, heavily weights the
two-tails of statistics and is sample-wise dependent [21].
FAIME.5 is an improved gene-set algorithm characterized
by individualized, non-parametric, and un-supervised
statistic (i.e., without the use of sample-wise estimation of
differential expression).
We introduced novel dynamic network biomarker ana-
lysis on the gene-set level (DNM analysis) to represent
LSC sub-populations. The identified gene-sets define
new biomarkers for the regulation of stem cell function
in AML, by characterizing dynamic features rather than
the static differences. DNM has the ability to discovery
significant regulatory changes of functional gene-sets
across disease progression stages. By taking into account
of a critical transition from normal state to disease state
during cell development, DNM outperforms other gene-
set analytic strategies in capturing critical signatures.
The proposed RXA-GSP (Relative Effect Analysis
with Functional gene-set-Group Pairs algorithm) is a
parameter-free model with respect to gene-sets and
is designed to bridge cancer biology from the lab to
the clinic [17,18]. It can be extended to other appli-
cations when analyzing biological imbalance within a
patient. RXA-GSP naturally fits the “two-hit hypothesis”
for malignancy: one leads to uncontrolled cellular prolif-
eration and evasion of apoptosis and the other adjusts in-
hibition of differentiation [41]. It is particularly useful for
efficiently translating microarray or RNA-seq data to
clinical discoveries.
Altogether, researchers can apply these proposed
computational strategies to study other diseases in a
systematic “gene-to-function, snapshot-to-dynamics,
and biology-to-clinic” framework. Previously, we have
successfully demonstrated the application of gene-to-
function (FAIME) on head and neck cancer, snapshot-to-
dynamics (DNB) on diabetes, and biology-to-clinic
(RXA-GSP) on breast cancer [7,16,17]. Increasing
evidence suggests the feasibility of analyzing an indi-
vidual’s transcriptome on a pathway-level for clinical
decision-making and precise mechanism comprehen-
sion. Additionally, different methods perform differ-
ently under different conditions or parameter settings
in their ability to detect the complex abnormality in
cancer. Researchers need to make ad hoc modifications
and select among analysis algorithms to make biological
discoveries.
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This work sheds promising insight into gene-set profiles
by defining the LSC- signature of 30-gene and the LSC+
signature of 25-gene for prognosis in AML. These signa-
tures suggest potential therapeutic regimens to eradicate
quiescent, chemotherapy-resistant LSCs, because they
exhibit two key characterizes - independence of cell
cycle status and not substrates for drug efflux pump pro-
teins [39]. The LSC- signature of 30-gene exposed a
promising molecular target, AURKA [26,27], to poten-
tially eliminate chemotherapy-resistance in LSC. The
LSC+ signature of 25-gene included known cancer genes
in the 12p13-p11.1 region [32] as well as genes in the
5q31.1 region [29] that are known to be associated with
myelodysplastic syndrome and AML. The only common
gene from both signatures, myeloperoxidase (MPO), is
implicated as a biomarker for favorable prognosis in
AML and its transcription levels reflect epigenetic modi-
fication [42]. This is not surprising because MPO is
known to be expressed by the myeloid lineage in AML
but not in HSC [43]. Given the complex system changes
in tumor progression, we expect that new gene-set
clusters could be prioritized using alternative GSEA
methods.
The two identified clusters of gene-sets significantly
predicted overall survival for 1478 primary AML pa-
tients, regardless of the inter-patient and intra-patient
variability of AML phenotypes. Their prognostic inde-
pendence is consistent with the published LSC-derived
prognostic signature. However, previously identified
genes are associated with adverse prognosis in AML
[22]. Our results suggest that the regulation of stem cell
function in AML also contains a favorable prognostic
component. Notably, the ability of LSC- representative
gene-sets to significantly stratify 548 patients with
cytogenetically normal AML is intriguing for preci-
sion medicine, as cytogenetically normal AML is dif-
ficult to stratify for patient outcomes. Evidence from
the literature further supports clinical relevance of
the identified DNM gene-sets and the selected con-
trol gene-sets. These LSC- control gene-sets included
published LSC highly-expressed genes that were pre-
viously associated with unfavorable event-free sur-
vival in patients with AML [22]. The LSC+ control
gene-sets included fenretinide-down-regulated genes
that were significantly correlated with poor-prognosis
in AML patients [44]. In contrast, the LSC- DNM
gene-sets are down-expressed in LSC and consist of
genes indicating good outcome (and/or) genes being
repressed by forskolin or IL2, two AML drugs that
stop blood cell differentiation or induce prolonged
remissions in advanced AML [45]. Genes associated
with the Scp2 GWAS study [29] are potential new drug
targets according to our results.Genes from the identified functional gene-sets signifi-
cantly share biological processes and molecular func-
tions, suggesting a new aspect of stem cell biology. The
questions of how these genes coordinate in the regula-
tion of stem cell function or determine “stemness” war-
rant future investigation. We confirmed the biological
co-expression of the LSC+ signature of 25-gene in AML
patients carrying positive RAS molecular activity. As
previous publications attest, it was RAS molecular activ-
ity rather than gene mutation that disturbed the identi-
fied LSC+ signaling and showed a prognostic factor.
In conclusion, LSC, or leukemia-initiating cell is a rare
cellular subpopulation that must be eradicated to cure a
patient of leukemia. However, their underlying mecha-
nisms remain a biological conundrum, partly due to
limited sample size and inter-patient and intra-patient
variability. This study proposes a comprehensive
knowledge-driven systematic analysis to functionally
characterize LSC collected by different laboratories,
followed by a novel dynamic network analysis. Two
identified LSC- subpopulation-specific gene-set clusters,
showing significant biological and clinical relevance,
have been validated independently. The proposed frame-
work extends our ability to re-use multiple layers of
“omics”-data, to derive a new gene-set from coordinated
gene-sets, and to discover new prognostic indicators,




All datasets were previously published (Additional file 4:
Table S4) and are publicly available. We have addition-
ally received written authorization from the authors of
GSE14468 to re-use the survival time of their samples.
All samples of patients with AML were obtained at the
time of diagnosis and with informed consent at corre-
sponding hospitals, and study protocols were approved
by the institutional review boards of corresponding insti-
tutes and hospitals [34,35,46,47].
Gene expression
We performed a literature review from PubMed, GEO,
and ArrayExpress for three keywords (“stem cell”,
“AML”, and “prognosis”) in October 2012. We collected
nine LSC studies (Table 1 and Additional file 4:
Table S1), two large primary AML datasets [35,46]
(n > 200 each) and samples from TCGA [34] (Additional
file 4: Table S4). We pooled sorted cell samples into
three groups defined by cell surface markers: AML
LSC-enriched cells (LSC+), AML LSC-depleted cells
(LSC-), and normal samples of sorted HSC-enriched
cells (HSC+). Only functionally defined LSC+ samples
(n = 77) were investigated, showing in vivo validated
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samples (n = 23) included diverse microarrays and RNA-
seq measurements (Table 1).
Functional gene-set
We studied three categories of previously defined func-
tional gene-sets from MSigDB (version 4.0) [19], with
variable numbers of member genes (Additional file 2:
Text S1: S Methods 2.1).
Functional gene-set profiles
Collapse multiple measurements per gene
To convert the gene-by-sample values into the gene-set-
by-sample scores, we first collapsed the gene expression
profiles to one value per sample for each unique gene,
using a selective collapsing strategy with the highest
average expression. This strategy has previously led to
the best inter-study consistency [48]. This step is neces-
sary to ensure equal gene representation as some genes
have multiple measurements on a microarray.
Calculate gene-set profiles
We calculated the FAIME-scores [7], the GSVA-scores
[21], and the new FAIME.α-scores using Equations 1, 2,
3, from all genes for each sample (j) (hereafter referred
to as the “gene-set profile”).
The null statistical hypothesis of a FAIME score is that
the weighted ranks of genes inside a gene-set and out-
side the gene-set are drawn from the same distribution.
In our calculations, we first converted the original gene
expression values to ranks (r (x)j) to reduce the influence
of potential outliers. Then we converted the ranks per
sample into a new scale (s (x)j) of continuous values to
softly award highly-expressed genes [20]. FAIME.5 em-
ploys qualitative scores sharply decreasing along gene
ranks by assigning the parameter α = 5 (Equation 1).
This strategy filters out low expressed genes and main-
tains cohort-independence.
Let i denote the gene-set index, by j the sample index,
x the gene index, and n the total number of measured
genes. Then





where the parameter α controls the rate at which the
weights rise when moving the list from the lowest ex-
pression ranks to the highest. A sequence of rapidly in-
creased weights (large α) is sensitive to the genes at the
extreme top of expression ranks (Figure 2B). Our previ-
ous research has shown that the ability to discriminate
between signal and noise critically depends on the ori-
ginal dataset [14], and a value of α = 1 was used in previ-
ous data [7].Given a set of genes {x1,…,xm}∈ gene-seti of size |gene-
seti|, we scored its activity function A() using Equation 2
and that for its complementary set GSi.
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Equation 3 defines a gene-set score which is the differ-
ence between the activity function of genes inside and
outside a previously defined gene-set.
FAIMEi;j αð Þ ¼ A x∈f GSi; αð Þj−A x∉ f GSi; αð Þj ð3Þ
Inter-dataset normalization
The goal of normalization was to compensate for tech-
nical differences and thus to make gene-set profiles from
different resources comparable [49,50]. Inter-dataset
normalization is implemented using the z-transform on
the gene-set profile f.j = {f1,f2,…fN} per sample j by divid-
ing by the standard deviation of the centered values,
which is denoted y.j in Equation 4. Y is a combined
matrix where rows correspond to pathways and columns
correspond to samples. This type of standardization has
been applied to two types of analyses: integrating gene-
set scores of differentially expressed genes and analyzing
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Unbiased simulation
To evaluate statistical power (sensitivity) and type-I
error, we carried out a simulation study as previously de-
scribed (Additional file 1: Figure S1) [21]. In short, nor-
malized and log-transformed gene expression values
were simulated for each gene a = {1,2,…p} and sample-
group b = {1,2} using the linear additive model in
Equation 5,
yab ¼ αa þ βb þ eab ð5Þ
where gene specific effect is αα ~N(0,1), sample specific
effect is βb ~ N(μj,σj), and random noise is eiab ~ N(0,1).
In the simulation study, we modeled p = 5000 genes
and two groups of samples each with different sample
size n = {10, 20, 40, 60, 80, 100}. We randomly built a
Yang et al. BMC Bioinformatics  (2015) 16:97 Page 18 of 21differentially expressed (DE) gene-set of 30 differentially-
expressed genes and a non-DE gene-set of 30 no-changed
genes, considering the following two facts for the DE
gene-set. 1) The fraction of differentially expressed genes
in the DE set varied, 50% and 80% respectively. 2) The ex-
pected signal-to-noise-ratio varied between weak and
strong, meaning that the magnitude of DE set between
two sample groups was 0.5 and 1. The simulation was
done by setting μ1 = μ2 = 0 with σ1 = σ2 = 1 for all genes in
the non-DE set but μ1 =m, μ2 = 0 with σ1 = σ2 = 0.5 for a
certain fraction of genes in the DE set. Then we applied
GSEA, GSVA, and FAIME modulating the parameter
α = {1, 5, 10} (Equations 1, 2, 3) on the simulated
gene expression data to generate the simulated gene-set
scores respectively. We repeated the above simulations
assigning the DE and non-DE gene-sets with x = {10, 20,
80, and 100}, i.e., 0.2%, 0.4%, 1.6%, and 2% of the modeled
5000 genes. The statistical power was a fraction of
significance for the DE set (true positive) whereas
the empirical type-I error was a fraction of the non-
adjusted significance (p < 0.05, two-sample t-test) of
the non-DE set. We adjusted the p-values for multiple-
testing across 1000 simulations [51] and set a significance
level of FDR = 0.05.
Dynamic Network Mechanism (DNM) analysis
DNM is built on dynamic network biomarker analysis
(DNB) [15], a model-free method to detect the dynamics
of disease developmental stage changes using gene ex-
pression profiles. Developed for gene-set profiling, DNM
identifies a cluster of gene-sets that highly co-fluctuate
in a “critical stage” (or disease transition stage). It ex-
plores the dynamic character of network nodes (gene-
sets) and links (alteration between gene-set pairs) across
sample groups. Given a sample group t = {LSC+, LSC-,
and normal HSC+} and the assigned control group (e.g.,
the normal HSC+), we performed the following five-step
calculation in our DNM analysis Figure 3.
1) To acquire candidate gene-sets with the highest
intra-group variation, we calculated the standard
deviation (SD) of every gene-set across samples
within this sample group. Then, we picked gene-sett,
the top 5% of all gene-sets having the highest SDs.
2) To cluster the gene-sett into highly co-variable
modules in a sample group t of interest, termed
CtI, we calculated the ‘intra-module’ correlation
of SDs (gene-sets were compared in pairs). We
ran an unsupervised hierarchical clustering on
overall pairwise Pearson correlation coefficients
(PCC). This agglomerative hierarchical clustering
was performed in R using complete linkage on
the pairwise PCC distance (1-PCC) in gene-sett.
A module of gene-sett consists of gene-sets thatsatisfy a significant level (p-value ≤ 0.01). Applying
a threshold of p-value ≤ 0.001 or p-value ≤ 0.05
also leads to comparable DNMs.
3) To estimate ‘inter-module’ co-variation within this
sample group t (CtI), we calculated the correlation of
SDs between CtI members and other control gene-sets.
We also estimated ‘cross-module’ co-variation between
this sample group t and control group (CtO). The
control gene-sets preserved the top n highest
correlations with any CtI members in the control
group but outside the CtI set. We applied n = 5
to small- or middle-sized gene-sets (pathways and
motifs) and n = 20 to the larger-sized gene-sets
(the CGPs).
4) To determine the critical sample group, we calculated
a combination score StI in Equation 6 [15] for each
module CtI in a given sample group t.
StI ¼ SDtI ⋅PCCIPCCo ð6Þ
where SDtI is the average SD value of gene-sets in the
CtI, PCCI represents the average PCC value of gene-set-
pairs in the CtI, and PCCo the average PCC value of
gene-sets between this CtI and CtO. The CtI with the lar-
gest StI score was then determined to comprise the
DNM markers and the corresponding sample group t to
be the critical sample group (disease stage).
5) Additionally, to assess the significance of gene
overlap among DNM gene-sets for a critical sample
group, we calculated the hypergeometric probability
using Equation 7 (Additional file 2: Text S1: S
Methods for inference). Given A, B, and C to be the
number of gene-set size for three DNM gene-sets
respectively, N = 22000 the background number of
human genes, n the observed number of shared
genes among DNM gene-sets, we calculated:























Prognosis of DNM gene-sets on primary AML samples
Previously, we proposed the concept of relative-
expression of gene-set pairs [17] which calculates a
prognostic indicator (Equation 8) for each patient.
An indicator of Relative Effect Analysis with Gene-set Pairs
Yang et al. BMC Bioinformatics  (2015) 16:97 Page 19 of 21(RXA-GSP) compares effects of DNM gene-sets with se-
lected control gene-sets, instead of genes, for each patient.
Ij S;Cð Þ ¼ f j Sð Þ−f j Cð Þ
 	





Based on the DNM analysis, we selected control gene-
sets {C} meeting the following two criteria: 1) significant
univariate analyses on overall survival of AML patients
(log-rank p < 0.01), and 2) a positive cox-regression coef-
ficient (i.e., increased scores of selected control gene-sets
are associated with poor outcome). We then derived a
sum-value Sj in Equation 9 for the DNM gene-set group
{S} and the control gene-set group {C}, respectively. The
sum-value is a linear combination of the gene-set scores
(indexed by i) weighted by the respective gene-set’ cox-
regression coefficient in the training set [47].









Gene-set scores of all identified DNM gene-sets and
their corresponding control gene-sets were calculated
for primary AML patients in three independent cohorts
to identify an indicator (Additional file 4: Table S4). We
set the largest cohort as the training set and used the
other two cohorts for validation. The treatment-related
AML patients and patients with prior malignancy or
leukemogenic agent exposure were excluded.
The Kaplan-Meier and the univariate Cox regression
analyses on both the training set and validation set dem-
onstrated the prognosticative power of the indicator. We
then asked whether the novel indicator remained prog-
nostic after adjusting by all other significant variables
that had a univariate p < 0.05, using multivariate testing.
Additionally, an empirical evaluation was performed
as suggested [52], by replacing the FAIME scores in
Equation 8 with randomly picked |S| and |C| gene-sets
from 3420 CGPs in the MSigDB database and repeating
the above two calculations X = 2000 times, where the
cardinality of a set S is denoted |S|. Then we estimated
the chance of observing the observed log-rank p-values
using Equation 10, the fraction of simulated p-values
that are less than or equal to the observed p-values.
p ¼ jp0log−rank≤pobserved j=X ð10Þ
Additional files
Additional file 1: Figure S1. Statistical power and type-I error rate in
unbiased simulations. Figure S2. Published LSC associated gene signatures
and their significantly enriched canonical pathways. Figure S3. Distribution
of pathway profiles for collected samples. Figure S4. Heatmap of genes inthe two DNM identified gene clusters from different datasets of three cell
subpopulations. Figure S5. Kaplan-Meier plots of patients with primary AML,
based on DNM identified gene-set pairs. Figure S6. Kaplan-Meier plots of
patients with primary AML, based on Gentles “LSC signature” [22].
Additional file 2: Text S1. Supplementary results, methods, and the
limitation.
Additional file 3: Text S2. R Code and demonstration for the function
rungene2pathway.
Additional file 4: Table S1. Nine studies and eight published gene
lists pertaining to AML LSC. Table S2. LSC- representative DNM
gene-sets (30-gene) and their control pairs in the normal state, derived
from gene-set profiles using the FAIME.5 algorithm. Table S3. LSC+
representative DNM gene-sets (25-gene) and their control pairs in the
normal states, derived from gene-set profiles using the GSVA algorithm.
Table S4. Three independent primary AML studies. Table S5. Univariate
and multivariate analyses of overall survival in patients with all types of AML,
for the LSC+ representative DNM gene-sets. Table S6. The somatic
mutations (of genes in the identified DNM gene-sets) and their patient
information in the TCGA database.
Additional file 5: Text S3. A tab-delimited text file recording the
normalized expression of the 54 identified genes.
Abbreviations
AML: Acute myeloid leukemia; CGP: Chemical and genetic perturbations;
CtI: ‘Inter-module’ co-variation within this sample group t; CtO: ‘Cross-
module’ co-variation between this sample group t and control group;
DNB: Dynamic network biomarker; DNM: Dynamic network mechanism;
SD: Standard deviation; ELN: European LeukemiaNet; FAIME: Functional
analysis of individual microarray (or RNA-seq) expression; FDR: False
discovery rate; IPA: Ingenuity pathway analysis; GO: Gene ontology; GS: Gene
set; GSEA: Gene set enrichment analysis; GSVA: Gene set variation analysis;
HSC+: Verified hematopoietic stem cells enriched; LSC: Leukemic stem cell;
LSC+: LSC enriched; LSC-: LSC depleted; MSigDB: Molecular signature
database; PCC: Pearson correlation coefficients; RXA-GSP: Relative effect
analysis with gene-set pairs.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XY, LC, and JMC designed the projects; JC supervised the prognostic analysis;
XY, LM, and BW analyzed data, WZ modeled the hypergeometric probability;
AD, JJ, KO, and XY interpreted the biological meaning; XY, LM, WZ, and AD
wrote the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank Dr. Gangqing Hu from National Heart, Lung and Blood Institute,
NIH, for providing the RPKM values for one CD34+ RNA-seq data, Peter J.M.
Valk, Ruud Delwel, and Bob Lowenberg from Department of Hematology,
Erasmus University Medical Center, Rotterdam, the Netherlands, for providing
the detailed survival information of their patients in the dataset GSE14468 to
support our secondary data analyses. We acknowledge The Cancer Genome
Atlas Consortium for providing detailed raw data. We thank Joshua
Stevens_Stein for his assistance editing this manuscript.
This work was supported by the National Institutes of Health [R21 CA167305-01A1
to Y.X., B.W., C.J, C.M.J]; 973 Project of China [2014CB910504 to C.L.], National
Natural Science Foundation of China [61134013, 91029301, and 11326035 to
C.L.], the Knowledge Innovation Program of CAS [KSCX2-EW-R-01 to C.L.], and
863 Project [2012AA020406 to C.L.]. Funding for open access charge: National
Institutes of Health [R21 CA167305-01A1].
Author details
1Department of Pediatrics, and Comer Children’s Hospital, Section of
Hematology/Oncology, The University of Chicago, 900 East 57th Street, KCBD
Room 5121, Chicago, Illinois 60637, USA. 2Key Laboratory of Systems Biology,
Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences, Shanghai, China. 3Department of
Medicine, The University of Chicago, Chicago, USA. 4Laboratory Schools, The
University of Chicago, Chicago, USA.
Yang et al. BMC Bioinformatics  (2015) 16:97 Page 20 of 21Received: 1 August 2014 Accepted: 24 February 2015References
1. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al.
Chemotherapy-resistant human AML stem cells home to and engraft within
the bone-marrow endosteal region. Nat Biotechnol. 2007;25(11):1315–21.
2. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, et al.
The sesquiterpene lactone parthenolide induces apoptosis of human
acute myelogenous leukemia stem and progenitor cells. Blood.
2005;105(11):4163–9.
3. Horton SJ, Huntly BJ. Recent advances in acute myeloid leukemia stem cell
biology. Haematologica. 2012;97(7):966–74.
4. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al.
A cell initiating human acute myeloid leukaemia after transplantation into
SCID mice. Nature. 1994;367(6464):645–8.
5. Wiseman DH, Greystoke BF, Somervaille TC. The variety of leukemic stem
cells in myeloid malignancy. Oncogene. 2014;33(24):3091–8.
6. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
et al. Gene set enrichment analysis: a knowledge-based approach for
interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A.
2005;102(43):15545–50.
7. Yang X, Regan K, Huang Y, Zhang Q, Li J, Seiwert TY, et al. Single sample
expression-anchored mechanisms predict survival in head and neck cancer.
PLoS Comput Biol. 2012;8(1):e1002350.
8. Yang X, Li H, Regan K, Li J, Huang Y, Lussier YA. Towards mechanism
classifiers: expression-anchored gene ontology signature predicts clinical
outcome in lung adenocarcinoma patients. AMIA Annu Symp Proc.
2012;2012:1040–9.
9. Tarca AL, Bhatti G, Romero R. A comparison of gene set analysis
methods in terms of sensitivity, prioritization and specificity. PLoS One.
2013;8(11):e79217.
10. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, et al. Inference of
patient-specific pathway activities from multi-dimensional cancer genomics
data using PARADIGM. Bioinformatics. 2010;26(12):i237–45.
11. Segal E, Friedman N, Koller D, Regev A. A module map showing conditional
activity of expression modules in cancer. Nat Genet. 2004;36(10):1090–8.
12. Drier Y, Sheffer M, Domany E. Pathway-based personalized analysis of
cancer. Proc Natl Acad Sci U S A. 2013;110(16):6388–93.
13. Xiong Q, Ancona N, Hauser ER, Mukherjee S, Furey TS. Integrating genetic
and gene expression evidence into genome-wide association analysis of
gene sets. Genome Res. 2012;22(2):386–97.
14. Yang X, Bentink S, Scheid S, Spang R. Similarities of ordered gene lists.
J Bioinform Comput Biol. 2006;4(3):693–708.
15. Chen L, Liu R, Liu ZP, Li M, Aihara K. Detecting early-warning signals for
sudden deterioration of complex diseases by dynamical network biomarkers.
Sci Rep. 2012;2:342.
16. Li M, Zeng T, Liu R, Chen L. Detecting tissue-specific early warning signals
for complex diseases based on dynamical network biomarkers: study of type
2 diabetes by cross-tissue analysis. Brief Bioinform. 2014;15(2):229–43.
17. Yang X, Vasudevan P, Parekh V, Penev A, Cunningham JM. Bridging cancer
biology with the clinic: relative expression of a GRHL2-mediated gene-set
pair predicts breast cancer metastasis. PLoS One. 2013;8(2):e56195.
18. Yang X, Ai X, Cunningham JM. Computational prognostic indicators for
breast cancer. Cancer Manage Res. 2014;6:301–12.
19. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P,
Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics.
2011;27(12):1739–40.
20. Lottaz C, Yang X, Scheid S, Spang R. OrderedList–a bioconductor
package for detecting similarity in ordered gene lists. Bioinformatics.
2006;22(18):2315–6.
21. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for
microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.
22. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic
stem cell gene expression signature with clinical outcomes in acute
myeloid leukemia. JAMA. 2010;304(24):2706–15.
23. de Jonge HJ, Woolthuis CM, Vos AZ, Mulder A, van den Berg E, Kluin PM,
et al. Gene expression profiling in the leukemic stem cell-enriched CD34+
fraction identifies target genes that predict prognosis in normal karyotype
AML. Leukemia. 2011;25(12):1825–33.24. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, et al.
Stem cell gene expression programs influence clinical outcome in human
leukemia. Nat Med. 2011;17(9):1086–93.
25. Ohashi S, Sakashita G, Ban R, Nagasawa M, Matsuzaki H, Murata Y, et al.
Phospho-regulation of human protein kinase Aurora-A: analysis using anti-
phospho-Thr288 monoclonal antibodies. Oncogene. 2006;25(59):7691–702.
26. Yang J, Ikezoe T, Nishioka C, Nobumoto A, Udaka K, Yokoyama A. CD34
(+)/CD38(−) acute myelogenous leukemia cells aberrantly express Aurora
kinase A. Int J Cancer. 2013;133(11):2706–19.
27. Kojima K, Shimanuki M, Shikami M, Andreeff M, Nakakuma H. Cyclin-
dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax
activation and mitochondrial apoptosis in AML. Cancer Sci.
2009;100(6):1128–36.
28. Graham SM, Vass JK, Holyoake TL, Graham GJ. Transcriptional analysis of
quiescent and proliferating CD34+ human hemopoietic cells from normal
and chronic myeloid leukemia sources. Stem Cells. 2007;25(12):3111–20.
29. Bystrykh L, Weersing E, Dontje B, Sutton S, Pletcher MT, Wiltshire T, et al.
Uncovering regulatory pathways that affect hematopoietic stem cell
function using ‘genetical genomics’. Nat Genet. 2005;37(3):225–32.
30. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood.
1994;84(10):3253–60.
31. Lai F, Godley LA, Joslin J, Fernald AA, Liu J, Espinosa 3rd R, et al. Transcript
map and comparative analysis of the 1.5-Mb commonly deleted segment
of human 5q31 in malignant myeloid diseases with a del(5q). Genomics.
2001;71(2):235–45.
32. Myllykangas S, Himberg J, Bohling T, Nagy B, Hollmen J, Knuutila S. DNA
copy number amplification profiling of human neoplasms. Oncogene.
2006;25(55):7324–32.
33. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ,
Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define
a subgroup of acute myeloid leukemia with a distinctive gene expression
profile that is uniquely associated with a favorable outcome. Blood.
2009;113(13):3088–91.
34. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of
adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–74.
35. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J,
Sauerland MC, et al. An 86-probe-set gene-expression signature
predicts survival in cytogenetically normal acute myeloid leukemia.
Blood. 2008;112(10):4193–201.
36. Venet D, Dumont JE, Detours V. Most random gene expression signatures
are significantly associated with breast cancer outcome. PLoS Comput Biol.
2011;7(10):e1002240.
37. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, et al. Gene mutation
patterns and their prognostic impact in a cohort of 1185 patients with
acute myeloid leukemia. Blood. 2011;118(20):5593–603.
38. Illmer T, Thiede C, Fredersdorf A, Stadler S, Neubauer A, Ehninger G, et al.
Activation of the RAS pathway is predictive for a chemosensitive phenotype
of acute myelogenous leukemia blasts. Clin Cancer Res. 2005;11(9):3217–24.
39. Becker MW, Jordan CT. Leukemia stemness signatures step toward the
clinic. Cell Stem Cell. 2011;9(3):185–6.
40. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches
and outstanding challenges. PLoS Comput Biol. 2012;8(2):e1002375.
41. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations
in epigenetic regulators in myeloid malignancies. Nat Rev Cancer.
2012;12(9):599–612.
42. Itonaga H, Imanishi D, Wong YF, Sato S, Ando K, Sawayama Y, et al.
Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the
distinct DNA methylation pattern involving the downregulation of DNA
methyltransferase DNMT3B. Leukemia. 2014;28(7):1459–66.
43. Leong AS-Y, Cooper K, Leong FJW-M. Manual of Diagnostic Antibodies for
Immunohistology Entnode. London: Greenwich Medical Media Ltd; 1999.
44. Zhang H, Mi JQ, Fang H, Wang Z, Wang C, Wu L, et al. Preferential
eradication of acute myelogenous leukemia stem cells by fenretinide.
Proc Natl Acad Sci U S A. 2013;110(14):5606–11.
45. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, et al. Interleukin-2
may induce prolonged remissions in advanced acute myelogenous
leukemia. Blood. 1994;84(7):2158–63.
46. Noordermeer SM, Sanders MA, Gilissen C, Tonnissen E, van der Heijden A,
Dohner K, et al. High BRE expression predicts favorable outcome in adult
acute myeloid leukemia, in particular among MLL-AF9-positive patients.
Blood. 2011;118(20):5613–21.
Yang et al. BMC Bioinformatics  (2015) 16:97 Page 21 of 2147. Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, et al. Identification of a
24-gene prognostic signature that improves the European LeukemiaNet risk
classification of acute myeloid leukemia: an international collaborative study.
J Clin Oncol. 2013;31(9):1172–81.
48. Miller JA, Cai C, Langfelder P, Geschwind DH, Kurian SM, Salomon DR, et al.
Strategies for aggregating gene expression data: the collapseRows R
function. BMC Bioinformatics. 2011;12:322.
49. Hansen KD, Irizarry RA, Wu Z. Removing technical variability in RNA-seq data
using conditional quantile normalization. Biostatistics. 2012;13(2):204–16.
50. Lim WK, Wang K, Lefebvre C, Califano A. Comparative analysis of microarray
normalization procedures: effects on reverse engineering gene networks.
Bioinformatics. 2007;23(13):i282–8.
51. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J Royal Stat Soc B
(Methodological). 1995;57(1):289–300.
52. Li J, Lenferink AE, Deng Y, Collins C, Cui Q, Purisima EO, et al. Identification
of high-quality cancer prognostic markers and metastasis network modules.
Nat Commun. 2010;1:34.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
